Keeping the memory of influenza viruses;Génération et persistance de la mémoire immunitaire contre les virus d'influenza

Pathologie Biologie

Volumn 58, Issue 2, 2010, Pages

  Combadiere B ^a,b   Siberil S ^a   Duffy, D ^a  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Effector memory cells; Immune memory; Influenza virus; Neutralizing antibodies

Indexed keywords

B LYMPHOCYTE ANTIBODY;

AGE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; INFLUENZA; INFLUENZA VIRUS; PANDEMIC; PHENOTYPE; REVACCINATION; T LYMPHOCYTE; VACCINATION;

ADULT; AGE DISTRIBUTION; AGED; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; B-LYMPHOCYTES; CHICKENS; CHILD; CHILD, PRESCHOOL; CROSS REACTIONS; DISEASE OUTBREAKS; EPITOPES; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LYMPHOCYTE SUBSETS; MIDDLE AGED; ORTHOMYXOVIRIDAE; T-LYMPHOCYTES;

EID: 77952376686     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2010.01.010     Document Type: Article

References (100)

1. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., Klenk H.D. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A 2004, 101:4620-4624.
2. Fauci A.S. Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act. Cell 2006, 124:665-670.
3. Morens D.M., Folkers G.K., Fauci A.S. The challenge of emerging and re-emerging infectious diseases. Nature 2004, 430:242-249.
4. Salomon R., Webster R.G. The influenza virus enigma. Cell 2009, 136:402-410.
5. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360:2605-2615.
6. Peiris J.S., Poon L.L., Guan Y. Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol 2009, 45:169-173.
7. Cohen J., Enserink M. Swine flu. After delays, WHO agrees: the 2009 pandemic has begun. Science 2009, 324:1496-1497.
8. W.H.O. Influenza vaccines; WHO position paper. Weekly Epidemiological Record (WER) 2005; 80:277-288.
9. Chowell G., Viboud C., Wang X., Bertozzi S., Miller M. Adaptive vaccination strategies to mitigate pandemic influenza: Mexico as a case study. PLoS Curr Influenza 2009, RRN1004.
10. Smith D.J., Forrest S., Ackley D.H., Perelson A.S. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A 1999, 96:14001-14006.
11. Greenbaum J.A., Kotturi M.F., Kim Y., Oseroff C., Vaughan K., Salimi N., et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009, 106:20365-20370.
12. Webster R.G., Rott R. Influenza virus A pathogenicity: the pivotal role of hemagglutinin. Cell 1987, 50:665-666.
13. De Groot A.S., Ardito M., McClaine E.M., Moise L., Martin W.D. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 2009, 27:5740-5747.
14. McMichael A.J., Gotch F.M., Noble G.R., Beare P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983, 309:13-17.
15. Chen G.L., Subbarao K. Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine. Nat Med 2009, 15:1251-1252.
16. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
17. Yu X., Tsibane T., McGraw P.A., House F.S., Keefer C.J., Hicar M.D., et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008, 455:532-536.
18. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025.
19. Doherty P.C., Turner S.J., Webby R.G., Thomas P.G. Influenza and the challenge for immunology. Nat Immunol 2006, 7:449-455.
20. Couch R.B. An overview of serum antibody responses to influenza virus antigens. Dev Biol (Basel) 2003, 115:25-30.
21. Jiang T., Li X., Liu W., Yu M., Liu J., Yu X., et al. Serum Antibody Response to the Novel Influenza A (H1N1) Virus in the Elderly. Clin Infect Dis 2010, 50:285-286.
22. Powers D.C., Belshe R.B. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 1993, 167:584-592.
23. Gorse G.J., Otto E.E., Powers D.C., Chambers G.W., Eickhoff C.S., Newman F.K. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J Infect Dis 1996, 173:285-290.
24. el-Madhun A.S., Cox R.J., Soreide A., Olofsson J., Haaheim L.R. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis 1998, 178:933-939.
25. El-Madhun A.S., Cox R.J., Haaheim L.R. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis 1999, 180:1356-1360.
26. de Bruijn I.A., Remarque E.J., Jol-van der Zijde C.M., van Tol M.J., Westendorp R.G., Knook D.L. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 1999, 179:31-36.
27. Davenport F.M., Hennessy A.V., Francis T. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 1953, 98:641-656.
28. Fazekas de St G., Webster R.G. Disquisitions of Original Antigenic Sin, I. Evidence in man. J Exp Med 1966, 124:331-345.
29. Anderson D.E., Carlos M.P., Nguyen L., Torres J.V. Overcoming original (antigenic) sin. Clin Immunol 2001, 101:152-157.
30. Kilbourne E.D., Smith C., Brett I., Pokorny B.A., Johansson B., Cox N. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A 2002, 99:10748-10752.
31. Marine W.M., Thomas J.E. Antigenic memory to influenza A viruses in man determined by monovalent vaccines. Postgrad Med J 1979, 55:98-104.
32. Frank A.L., Taber L.H. Variation in frequency of natural reinfection with influenza A viruses. J Med Virol 1983, 12:17-23.
33. Glezen W.P., Couch R.B., Taber L.H., Paredes A., Allison J.E., Frank A.L., et al. Epidemiologic observations of influenza B virus infections in Houston Texas, 1976-1977. Am J Epidemiol 1980, 111:13-22.
34. Wood J.M., Nicholson K.G., Stephenson I., Zambon M., Newman R.W., Major D.L., et al. Experience with the clinical development of influenza vaccines for potential pandemics. Med Microbiol Immunol 2002, 191:197-201.
35. Simonsen L., Clarke M.J., Schonberger L.B., Arden N.H., Cox N.J., Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998, 178:53-60.
36. Ahmed R., Oldstone M.B., Palese P. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol 2007, 8:1188-1193.
37. Taubenberger J.K., Morens D.M. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006, 12:15-22.
38. Frank A.L., Taber L.H., Glezen W.P., Paredes A., Couch R.B. Reinfection with influenza A (H3N2) virus in young children and their families. J Infect Dis 1979, 140:829-836.
39. Virelizier J.L., Allison A.C., Schild G.C. Antibody responses to antigenic determinants of influenza virus hemagglutinin, II. Original antigenic sin: a bone marrow-derived lymphocyte memory phenomenon modulated by thymus-derived lymphocytes. J Exp Med 1974, 140:1571-1578.
40. Virelizier J.L., Postlethwaite R., Schild G.C., Allison A.C. Antibody responses to antigenic determinants of influenza virus hemagglutinin, I. Thymus dependence of antibody formation and thymus independence of immunological memory. J Exp Med 1974, 140:1559-1570.
41. Hilleman M.R. Six decades of vaccine development--a personal history. Nat Med 1998, 4:507-514.
42. Hilleman M.R. Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology. Immunol Rev 1999, 170:7-27.
43. Bodmer H., Ogg G., Gotch F., McMichael A. Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes. Nature 1989, 342:443-446.
44. Gotch F., McMichael A., Smith G., Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 1987, 165:408-416.
45. McMichael A.J., Gotch F.M., Rothbard J. HLA B37 determines an influenza A virus nucleoprotein epitope recognized by cytotoxic T lymphocytes. J Exp Med 1986, 164:1397-1406.
46. McMichael A.J., Gotch F.M., Santos-Aguado J., Strominger J.L. Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1988, 85:9194-9198.
47. McMichael A.J., Michie C.A., Gotch F.M., Smith G.L., Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 1986, 67(Pt 4):719-726.
48. Townsend A.R., Rothbard J., Gotch F.M., Bahadur G., Wraith D., McMichael A.J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986, 44:959-968.
49. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2:251-262.
50. Sprent J., Surh C.D. Generation and maintenance of memory T cells. Curr Opin Immunol 2001, 13:248-254.
51. Combadiere B., Boissonnas A., Carcelain G., Lefranc E., Samri A., Bricaire F., et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004, 199:1585-1593.
52. Puissant-Lubrano B., Combadiere B., Duffy D., Wincker N., Frachette M.J., Ait-Mohand H., et al. Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients. Vaccine 2009, 27:3576-3583.
53. Bossi P., Gay F., Fouzai I., Combadiere B., Brousse G., Lebrun-Vignes B., et al. Demographic and clinical factors associated with response to smallpox vaccine in preimmunized volunteers. PLoS One 2008, 3:e4087.
54. Puissant B., Combadiere B. Keeping the memory of smallpox virus. Cell Mol Life Sci 2006, 63:2249-2259.
55. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131-1137.
56. Murali-Krishna K., Lau L.L., Sambhara S., Lemonnier F., Altman J., Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 1999, 286:1377-1381.
57. Wherry E.J., Barber D.L., Kaech S.M., Blattman J.N., Ahmed R. Antigen-independent memory CD8 T cell s do not develop during chronic viral infection. Proc Natl Acad Sci U S A 2004, 101:16004-16009.
58. Bender B.S., Croghan T., Zhang L., Small P.A. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 1992, 175:1143-1145.
59. Belz G.T., Stevenson P.G., Doherty P.C. Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza A viruses. J Immunol 2000, 165:2404-2409.
60. Doherty P.C., Hou S., Tripp R.A. CD8+ T-cell memory to viruses. Curr Opin Immunol 1994, 6:545-552.
61. Epstein S.L., Lo C.Y., Misplon J.A., Bennink J.R. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 1998, 160:322-327.
62. Graham M.B., Braciale T.J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 1997, 186:2063-2068.
63. Pala P., Townsend A.R., Askonas B.A. Viral recognition by influenza A virus cross-reactive cytotoxic T (Tc) cells: the proportion of Tc cells that recognize nucleoprotein varies between individual mice. Eur J Immunol 1986, 16:193-198.
64. Vogt A., Mahe B., Costagliola D., Bonduelle O., Hadam S., Schaefer G., et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J Immunol 2008, 180:1482-1489.
65. Seo S.H., Peiris M., Webster R.G. Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. J Virol 2002, 76:4886-4890.
66. Seo S.H., Webster R.G. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 2001, 75:2516-2525.
67. O'Neill E., Krauss S.L., Riberdy J.M., Webster R.G., Woodland D.L. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 2000, 81:2689-2696.
68. Ernst W.A., Kim H.J., Tumpey T.M., Jansen A.D., Tai W., Cramer D.V., et al. Protection against H1, H5. H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006, 24:5158-5168.
69. Suguitan A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006, 3:e360.
70. Govorkova E.A., Rehg J.E., Krauss S., Yen H.L., Guan Y., Peiris M., et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 2005, 79:2191-2198.
71. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005, 191:1210-1215.
72. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003, 21:1687-1693.
73. Grubeck-Loebenstein B., Della Bella S., Iorio A.M., Michel J.P., Pawelec G., Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009, 21:201-209.
74. Sambhara S., McElhaney J.E. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol 2009, 333:413-429.
75. Joshi S.R., Shaw A.C., Quagliarello V.J. Pandemic influenza H1N1 2009, innate immunity, and the impact of immunosenescence on influenza vaccine. Yale J Biol Med 2009, 82:143-151.
76. He X.S., Holmes T.H., Sasaki S., Jaimes M.C., Kemble G.W., Dekker C.L., et al. Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One 2008, 3:e2574.
77. McElhaney J.E., Hooton J.W., Hooton N., Bleackley R.C. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 2005, 23:3294-3300.
78. Gross P.A., Weksler M.E., Quinnan G.V., Douglas R.G., Gaerlan P.F., Denning C.R. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 1987, 25:1763-1765.
79. McElhaney J.E. Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines. Aging Health 2008, 4:603-613.
80. McElhaney J.E., Gravenstein S., Upshaw C.M., Hooton J.W., Krause P., Drinka P., et al. Granzyme B: a marker of risk for influenza in institutionalized older adults. Vaccine 2001, 19:3744-3751.
81. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351:2295-2301.
82. Raz E., Carson D.A., Parker S.E., Parr T.B., Abai A.M., Aichinger G., et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A 1994, 91:9519-9523.
83. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001, 1:209-219.
84. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
85. Bos J.D., Kapsenberg M.L. The skin immune system: progress in cutaneous biology. Immunol Today 1993, 14:75-78.
86. Kupper T.S., Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004, 4:211-222.
87. Charest A.F., McDougall J., Goldstein M.B. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000, 36:976-982.
88. Egemen A., Aksit S., Kurugol Z., Erensoy S., Bilgic A., Akilli M. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children. Vaccine 1998, 16:1511-1515.
89. Combadiere B., Mahe B. Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 2008, 31:293-315.
90. Mahe B., Vogt A., Liard C., Duffy D., Abadie V., Bonduelle O., et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 2009, 129:1156-1164.
91. Abadie V., Bonduelle O., Duffy D., Parizot C., Verrier B., Combadiere B. Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice. PLoS One 2009, 4:e8159.
92. Humphreys T.L., Baldridge L.A., Billings S.D., Campbell J.J., Spinola S.M. Trafficking pathways and characterization of CD4 and CD8 cells recruited to the skin of humans experimentally infected with Haemophilus ducreyi. Infect Immun 2005, 73:3896-3902.
93. Robert C., Kupper T.S. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999, 341:1817-1828.
94. Abadie V., Badell E., Douillard P., Ensergueix D., Leenen P.J., Tanguy M., et al. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 2005, 106:1843-1850.
95. Ennis F.A., Cruz J., Jameson J., Klein M., Burt D., Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 1999, 259:256-261.
96. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29:497-510.
97. Belyakov I.M., Ahlers J.D., Berzofsky J.A. Mucosal AIDS vaccines: current status and future directions. Expert Rev Vaccines 2004, 3:S65-73.
98. Le Borgne M., Etchart N., Goubier A., Lira S., Sirard J., van Rooijen N., et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 2006, 24:191-201.
99. Vogt A., Combadiere B., Hadam S., Stieler K.M., Lademann J., Schaefer H., et al. 40nm, but not 750 or 1,500nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol 2006, 126:1316-1322.
100. Vogt A., Mandt N., Lademann J., Schaefer H., Blume-Peytavi U. Follicular targeting--a promising tool in selective dermatotherapy. J Investig Dermatol Symp Proc 2005, 10:252-255.